Your browser doesn't support javascript.
loading
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis.
Martín, Miguel; Chacón, José I; Antón, Antonio; Plazaola, Arrate; García-Martínez, Elena; Seguí, Miguel A; Sánchez-Rovira, Pedro; Palacios, José; Calvo, Lourdes; Esteban, Carmen; Espinosa, Enrique; Barnadas, Agusti; Batista, Norberto; Guerrero, Angel; Muñoz, Montserrat; Romio, Estefania; Rodríguez-Martín, César; Caballero, Rosalía; Casas, María I; Rojo, Federico; Carrasco, Eva; Antolín, Silvia.
Afiliação
  • Martín M; Oncology Department, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain mmartin@geicam.org.
  • Chacón JI; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain, on behalf of GEICAM (Spanish Breast Cancer Group), Spain.
  • Antón A; Oncology Department, Hospital Universitario Virgen de la Salud, Toledo, Spain.
  • Plazaola A; Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • García-Martínez E; Oncology Department, Onkologikoa, San Sebastián, Spain.
  • Seguí MA; Oncology Department, Hospital General Universitario Morales Messeguer, Murcia, Spain.
  • Sánchez-Rovira P; Oncology Department, Corporación Sanitaria Parc Taulí, Barcelona, Spain.
  • Palacios J; Oncology Department, Complejo Hospitalario de Jaén, Jaén, Spain.
  • Calvo L; Pathology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Esteban C; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain, on behalf of GEICAM (Spanish Breast Cancer Group), Spain.
  • Espinosa E; Oncology Department, Complejo Hospitalario Universitario de la Coruña, La Coruña, Spain.
  • Barnadas A; Oncology Department, Hospital Universitario Virgen de la Salud, Toledo, Spain.
  • Batista N; Oncology Department, Hospital Universitario la Paz, Madrid, Spain.
  • Guerrero A; Medical Oncology Department, Hospital de Santa Creu i Sant Pau, Institut de Recerca IIB Sant Pau, Barcelona, Spain.
  • Muñoz M; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain, on behalf of GEICAM (Spanish Breast Cancer Group), Spain.
  • Romio E; Oncology Department, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain.
  • Rodríguez-Martín C; Oncology Department, Instituto Valenciano de Oncología, Valencia, Spain.
  • Caballero R; Oncology Department, Hospital Clinic i Provincial, Barcelona, Spain.
  • Casas MI; Pathology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Rojo F; GEICAM headquarters, Madrid, Spain.
  • Carrasco E; GEICAM headquarters, Madrid, Spain.
  • Antolín S; GEICAM headquarters, Madrid, Spain.
Oncologist ; 22(11): 1301-1308, 2017 11.
Article em En | MEDLINE | ID: mdl-28701571
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article